Equillium Inc. does not pay cash dividends to its common shareholders, as the enterprise operates as a clinical-stage biotechnology firm. Management directs all available financial resources, cash reserves, and partnership proceeds toward funding intensive research and development, clinical trial execution, and the progression of its novel immunobiology pipeline.